Skip to main content
Premium Trial:

Request an Annual Quote

Archer Reveal ctDNA Assay

ArcherDX has launched its Archer Reveal ctDNA assay which includes full-exon coverage of the tumor suppressor TP53 as a general marker of malignancy. It was designed for high-throughput laboratories and utilizes the company's lyophilized reagents and automated bioinformatics analysis. The assay generates NGS libraries using a little as 1ng circulating, cell-free tumor DNA and requires only 5 million paired-end reads. It is also very fast and can easily generate over 24 different libraries in less than 7 hours, the company said.